UY37015A - Inhibidores de la tirosina quinasa de bruton y métodos de su uso - Google Patents

Inhibidores de la tirosina quinasa de bruton y métodos de su uso

Info

Publication number
UY37015A
UY37015A UY0001037015A UY37015A UY37015A UY 37015 A UY37015 A UY 37015A UY 0001037015 A UY0001037015 A UY 0001037015A UY 37015 A UY37015 A UY 37015A UY 37015 A UY37015 A UY 37015A
Authority
UY
Uruguay
Prior art keywords
methods
inhibitors
tyrosine kinase
bruton tyrosine
bruton
Prior art date
Application number
UY0001037015A
Other languages
English (en)
Spanish (es)
Inventor
Nidhi Arora
M Bacani Genesis
Kent Barbay Joseph
D Bembenek Scott
Min Cai
Pooley Deckhut Charlotte
Brahmananda Ghosh
Gang Li
S Tichenor Mark
D Venable Jennifer
Jianmei Wei
J M Wiener John
Yao Wu
Yaoping Zhu
Feihuang Zhang
Kun Xiao
Wei Chen
P Edwards James
D Kreutter Kevin
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of UY37015A publication Critical patent/UY37015A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UY0001037015A 2015-12-10 2016-12-09 Inhibidores de la tirosina quinasa de bruton y métodos de su uso UY37015A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562265836P 2015-12-10 2015-12-10

Publications (1)

Publication Number Publication Date
UY37015A true UY37015A (es) 2017-06-30

Family

ID=57681784

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037015A UY37015A (es) 2015-12-10 2016-12-09 Inhibidores de la tirosina quinasa de bruton y métodos de su uso

Country Status (30)

Country Link
US (5) US10717745B2 (enExample)
EP (2) EP3386991B1 (enExample)
JP (2) JP6835846B2 (enExample)
KR (1) KR102103395B1 (enExample)
CN (2) CN113121562B (enExample)
AR (1) AR107042A1 (enExample)
AU (1) AU2016366541B2 (enExample)
BR (1) BR112018011526B1 (enExample)
CA (1) CA3007990C (enExample)
CY (1) CY1123263T1 (enExample)
DK (1) DK3386991T3 (enExample)
EA (1) EA035168B1 (enExample)
ES (1) ES2805835T3 (enExample)
HR (1) HRP20201193T1 (enExample)
HU (1) HUE049502T2 (enExample)
IL (1) IL259863B (enExample)
JO (1) JO3794B1 (enExample)
LT (1) LT3386991T (enExample)
MA (2) MA43409B1 (enExample)
MD (1) MD3386991T2 (enExample)
ME (1) ME03803B (enExample)
MX (1) MX387590B (enExample)
PL (1) PL3386991T3 (enExample)
PT (1) PT3386991T (enExample)
RS (1) RS60604B1 (enExample)
SI (1) SI3386991T1 (enExample)
SM (1) SMT202000404T1 (enExample)
TW (1) TWI729047B (enExample)
UY (1) UY37015A (enExample)
WO (1) WO2017100662A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) * 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為malt1抑制劑之吡唑衍生物
WO2018170220A1 (en) * 2017-03-15 2018-09-20 Janssen Sciences Ireland Uc Methods of selective aryl- and heteroaryl-nitrogen bond formation
CN108164397B (zh) * 2018-01-18 2020-11-13 暨南大学 一类邻苯二酚衍生物及其制备方法
MX2020012204A (es) 2018-06-11 2021-03-31 Amgen Inc Inhibidores de kras g12c para tratar el cáncer.
KR20210151880A (ko) 2019-04-11 2021-12-14 얀센 파마슈티카 엔.브이. Malt1 억제제로서의 피리딘 고리 함유 유도체
US20230094146A1 (en) * 2020-01-07 2023-03-30 Medshine Discovery Inc. Deuterated thienopyridine compound
JP2024509828A (ja) * 2021-03-03 2024-03-05 ヤンセン ファーマシューティカ エヌ.ベー. Malt1阻害剤及びbtk阻害剤を使用する併用療法
IL308951A (en) 2021-06-04 2024-01-01 Janssen Pharmaceutica Nv Inhibitors of proton tyrosine kinase and methods of using them
CA3223610A1 (en) 2021-06-30 2023-01-05 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
MX2024001840A (es) 2021-08-09 2024-02-28 Janssen Pharmaceutica Nv Composiciones para usar en el tratamiento de neoplasias de celulas b.
EP4479405A1 (en) * 2022-02-18 2024-12-25 JANSSEN Pharmaceutica NV Synthesis of bruton's tyrosine kinase inhibitors
WO2025262118A1 (en) 2024-06-20 2025-12-26 Janssen Pharmaceutica Nv Combination therapy using a malt1 inhibitor and a btk inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3112415A1 (de) 1981-03-28 1982-10-07 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden
US5430150A (en) 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5300478A (en) 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
CN101056639A (zh) 2004-09-15 2007-10-17 詹森药业有限公司 噻唑并吡啶激酶抑制剂
WO2006118749A1 (en) * 2005-05-04 2006-11-09 Janssen Pharmaceutica, N.V. Thia-tetraazaacenaphthylene kinase inhibitors
AU2006278627B2 (en) 2005-08-08 2011-08-18 Janssen Pharmaceutica, N.V. Thiazolopyrimidine kinase inhibitors
WO2007092879A2 (en) * 2006-02-08 2007-08-16 Janssen Pharmaceutica, N.V. Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
ES2673973T3 (es) 2006-09-22 2018-06-26 Pharmacyclics Llc Inhibidores de tirosina cinasa de Bruton
WO2010056875A1 (en) * 2008-11-12 2010-05-20 Cgi Pharmaceuticals, Inc. Pyridazinones and their use as btk inhibitors
US8486965B2 (en) 2009-08-26 2013-07-16 Takeda Pharmaceutical Company Limited Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer
US9371567B2 (en) 2010-04-19 2016-06-21 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of BTK inhibitors
FR2978441A1 (fr) 2011-07-25 2013-02-01 Diverchim Nouveaux analogues de ceramides, leurs procedes de preparation et leurs applications dans les compositions pharmaceutiques et cosmetiques
SI2970291T1 (sl) 2013-03-15 2022-07-29 Janssen Pharmaceutica, N.V. Postopki in vmesne spojine za pripravo zdravila
EA030538B1 (ru) * 2013-12-11 2018-08-31 Байоджен Ма Инк. Биарильное соединение, применяемое при лечении заболеваний человека в онкологии, неврологии и иммунологии
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
WO2018103060A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
WO2018103058A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use

Also Published As

Publication number Publication date
EP3386991B1 (en) 2020-06-03
DK3386991T3 (da) 2020-07-13
JP2021073286A (ja) 2021-05-13
US11319329B2 (en) 2022-05-03
JO3794B1 (ar) 2021-01-31
AU2016366541A1 (en) 2018-05-31
HRP20201193T1 (hr) 2020-11-13
US20230097422A1 (en) 2023-03-30
NZ742484A (en) 2021-09-24
TW201734021A (zh) 2017-10-01
CN113121562A (zh) 2021-07-16
JP6835846B2 (ja) 2021-02-24
SI3386991T1 (sl) 2020-08-31
EA201891378A1 (ru) 2018-12-28
JP7072690B2 (ja) 2022-05-20
CA3007990C (en) 2024-01-02
CN113121562B (zh) 2022-09-13
ME03803B (me) 2021-04-20
HUE049502T2 (hu) 2020-09-28
LT3386991T (lt) 2020-08-25
ES2805835T3 (es) 2021-02-15
CY1123263T1 (el) 2021-12-31
US10934310B2 (en) 2021-03-02
JP2018536686A (ja) 2018-12-13
CA3007990A1 (en) 2017-06-15
AU2016366541B2 (en) 2021-05-13
BR112018011526A2 (pt) 2018-11-21
BR112018011526B1 (pt) 2024-02-27
US20190276471A1 (en) 2019-09-12
PL3386991T3 (pl) 2021-03-08
KR102103395B1 (ko) 2020-04-23
RS60604B1 (sr) 2020-08-31
AR107042A1 (es) 2018-03-14
SMT202000404T1 (it) 2020-09-10
PT3386991T (pt) 2020-08-18
MX2018007075A (es) 2018-11-09
US20170283430A1 (en) 2017-10-05
MX387590B (es) 2025-03-18
EP3719022A1 (en) 2020-10-07
US10717745B2 (en) 2020-07-21
WO2017100662A1 (en) 2017-06-15
IL259863A (en) 2018-07-31
EA035168B1 (ru) 2020-05-08
IL259863B (en) 2020-06-30
US20210101910A1 (en) 2021-04-08
CN108884106A (zh) 2018-11-23
US20240383914A1 (en) 2024-11-21
MA43409B1 (fr) 2020-10-28
TWI729047B (zh) 2021-06-01
US12065446B2 (en) 2024-08-20
MA53110A (fr) 2021-05-12
KR20180093974A (ko) 2018-08-22
EP3386991A1 (en) 2018-10-17
MD3386991T2 (ro) 2020-11-30

Similar Documents

Publication Publication Date Title
UY37015A (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
MX2018007084A (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
ECSP19089214A (es) Inhibidores de quinasa y usos de los mismos
MX385082B (es) Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos.
NI201700095A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
MX2015011514A (es) Compuestos de heteroarilo y sus usos.
CR20150524A (es) Compuestos de heteroarilo y sus usos
GT201400178A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
ECSP15043696A (es) Compuestos de heteroarilo y sus usos
MX2016015743A (es) Compuestos de ciclopropilamina como inhibidores de histona demetilasa.
EA201692219A1 (ru) Способы получения противовирусных соединений
MX387487B (es) Compuestos polifluorados que actúan como inhibidores de la tirosina cinasa de bruton.
EA201492056A1 (ru) Пиримидиниловые ингибиторы тирозинкиназы
UY35500A (es) Indazoles sustituidos con heteroarilo
MX2017014459A (es) Compuestos de tioeter como inhibidores de la nitrificacion.
MX2015009719A (es) Inhibidores benzoquinolona de vmat2.
MX2017007377A (es) Compuestos organicos.
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
MX374555B (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
DOP2015000176A (es) Compuestos de azetidiniloxifenilpirrolidina
UY35876A (es) Derivados de pirazolopirimidin-2-ilo como inhibidores de jak
BR112018005795A2 (pt) inibidor de quinase de egfr e método de preparação e seu uso

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20231226